Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,033 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clotting Disorder Clear all
Completed Phase 3 Interventional Results available

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

NCT00056550
View directory record Official record
Conditions
Antithrombin Deficiency, Congenital
Interventions
Recombinant Human Antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Marietta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

NCT03064035
View directory record Official record
Conditions
Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Interventions
4-factor prothrombin complex concentrate (4FPCC)
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 125 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 24, 2026, 2:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge

NCT03139097
View directory record Official record
Conditions
Coagulation
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Baltimore, Maryland • Raleigh, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

NCT02256917
View directory record Official record
Conditions
Severe Haemophilia A
Interventions
Human cl rhFVIII
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 24, 2026, 2:24 AM EDT
Not listed No phase listed Observational

Pharmacogenomics of Warfarin in Hispanics and Latinos

NCT02972385
View directory record Official record
Conditions
Thrombosis, Hemorrhage
Interventions
Mouthwash sample, Blood Draw
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

NCT00816660
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 24, 2026, 2:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots

NCT00584610
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Levonorgestrel-containing IUD (Mirena®), Copper-containing IUD (Paraguard®)
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 18, 2010 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

NCT02289703
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Rivaroxaban 15 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 24, 2026, 2:24 AM EDT
Active, not recruiting No phase listed Observational

Analysis of Specimens From Individuals With Pulmonary Fibrosis

NCT00084305
View directory record Official record
Conditions
Pulmonary Fibrosis, Healthy Volunteers, Hermansky-Pudlak Syndrome (HPS)
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 115 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 2:24 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

NCT02027779
View directory record Official record
Conditions
Hemophilia A
Interventions
GreenGene™ F
Biological
Lead sponsor
Green Cross Corporation
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Gene - Exercise Research Study

NCT00976742
View directory record Official record
Conditions
Cardiovascular Disease Risk Factors
Interventions
Endurance exercise training
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
50 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

NCT00956345
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Cincinnati, Ohio • Portland, Oregon • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

NCT00586651
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocytosis
Interventions
lestaurtinib
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 3 Interventional

Is Plasma Transfusion Beneficial Prior to Low-Risk Procedures in Hospitalized Patients With Blood Clotting Abnormalities?

NCT00953901
View directory record Official record
Conditions
Blood Coagulation, Disorders, Surgical Procedures, Minimally Invasive
Interventions
Fresh Frozen Plasma Transfusion
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2009 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

NCT00376922
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 2:24 AM EDT
Completed No phase listed Observational

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

NCT03405337
View directory record Official record
Conditions
Hemophilia A
Interventions
FVIII products, Conventional FVIII replacement therapies
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

NCT03393975
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755, Standard of care
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
0 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

NCT01253811
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 6 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease

NCT00212485
View directory record Official record
Conditions
Inherited Bleeding Disorders
Interventions
Power Doppler Sonography, MRI
Procedure
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
1 Year to 60 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2010 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Not applicable Interventional Results available

The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass

NCT01435304
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
method of returning residual CPB blood ( Hemobag®)
Device
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 24, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Phase I/IIa Study of FIXFc in Hemophilia B Patients

NCT00716716
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 2:24 AM EDT
Completed No phase listed Observational

The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry

NCT00328133
View directory record Official record
Conditions
Traumatic Hemorrhage, Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 24, 2026, 2:24 AM EDT
Terminated Not applicable Interventional

Osteoporosis and MRI Study in Hemophilia

NCT01460147
View directory record Official record
Conditions
Bone Mineral Density, Hemophilia A, Hemophilia B
Interventions
DXA scan + MRI
Other
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
25 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 24, 2026, 2:24 AM EDT
Withdrawn Phase 4 Interventional

PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care

NCT00377143
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Warfarin Dosing
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 24, 2026, 2:24 AM EDT